

**PROTOKOLL FRA
ORDINÆR GENERALFORSAMLING**

**MINUTES OF
ANNUAL GENERAL MEETING**

I

OF

EXACT THERAPEUTICS AS

EXACT THERAPEUTICS AS

ORG. NR. 998 317 487

REG. NO. 998 317 487

Den 9. juni 2023 kl. 10.30 ble det avholdt ordinær generalforsamling i EXACT Therapeutics AS ("**Selskapet**").

The Annual General Meeting of EXACT Therapeutics AS (the "**Company**") was held on 9 June 2023 at 10:30 hours (CEST).

Generalforsamlingen ble avholdt digitalt.

The General Meeting was held electronically.

I henhold til fortegnelsen inntatt i Vedlegg 1 var 16.203.125 av totalt 29.997.219 utstedte aksjer og stemmer, som tilsvarer 54,02% av det totale antall stemmeberettigede aksjer i Selskapet, representert på generalforsamlingen.

According to the record included as Appendix 1, 16,203,125 of a total of 29,997,219 issued shares and votes, corresponding to 54.02 % of the total number of voting shares in the Company, were represented at the General Meeting.

Følgende saker ble behandlet:

The following matters were considered:

**1 ÅPNING AV
GENERALFORSAMLINGEN,
GODKJENNELSE AV INNKALLING
OG DAGSORDEN**

**1 OPENING OF THE GENERAL
MEETING, APPROVAL OF THE
SUMMONS AND AGENDA**

Styrelederen reiste spørsmål om det var noen bemerkninger til innkallingen eller dagsordenen. Da det ikke var noen innvendinger, ble innkallingen og dagsordenen ansett som godkjent. Styreleder erklærte generalforsamlingen for lovlig satt.

The Chair asked whether there were any objections to the notice or the agenda. No such objections were raised. The notice and the agenda were thus considered approved. The Chair declared the General Meeting as lawfully convened.

**2 VALG AV MØTELEDER OG ÉN
PERSON TIL Å MEDUNDERTEGNE
PROTOKOLLEN**

**2 ELECTION OF CHAIR AND PERSON
TO CO-SIGN THE MINUTES**

Anders Wold ble valgt til møteleder. John M. Edminson ble valgt til å undertegne protokollen sammen med møtelederen.

Anders Wold was elected to chair the meeting. John M. Edminson was elected to sign the minutes together with the Chair of the meeting.

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

3 GODKJENNING AV ÅRSREGNSKAP OG STYRETS ÅRSBERETNING

I samsvar med styrets forslag ble følgende vedtatt:

Årsregnskapet, herunder konsernregnskap og årsberetning for regnskapsåret 2022, godkjennes. Det utdeles ikke utbytte for regnskapsåret 2022.

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

3 APPROVAL OF THE FINANCIAL STATEMENTS AND THE BOARD OF DIRECTORS' REPORT

In accordance with the Board of Director's proposal, the following resolution was made:

The annual accounts, including the group's annual accounts and the Board of Directors' report for the financial year 2022, are approved. No dividend is distributed for the financial year 2022.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

4 GODKJENNELSE AV HONORAR TIL REVISOR

I samsvar med styrets forslag ble følgende vedtatt:

"Generalforsamlingen godkjenner honoraret til revisor for regnskapsåret 2022 på NOK 330.000."

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

4 APPROVAL OF THE AUDITOR REMUNERATION

In accordance with the Board of Director's proposal, the following resolution was made:

"The General Meeting approves the remuneration to the auditor for the financial year 2022 of NOK 330,000."

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

5 VALG AV STYREMEDLEMMER

Anders Wold, Masha Strømme, Sir William Castell og Ann-Tove Kongsnes er alle på valg. Jean-Michel Cosséry tar ikke gjenvalg.

I samsvar med nominasjonskomiteens forslag besluttet generalforsamlingen å velge følgende styresammensetning:

- Anders Wold (Styrets leder)
- Masha Strømme (nestleder)
- Sir William Castell

5 ELECTION OF BOARD MEMBERS

Anders Wold, Masha Strømme, Sir William Castell and Ann-Tove Kongsnes are all up for election. Jean-Michel Cosséry is not seeking re-election.

In accordance with the Nomination Committee's proposal, the following Board composition was made:

- Anders Wold (Chair)
- Masha Strømme (Vice-Chair)
- Sir William Castell

- Ann-Tove Kongsnes

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

6 VALG AV MEDLEMMER TIL NOMINASJONSKOMITEEN

Samtlige medlemmer av nominasjonskomiteen er på valg.

I samsvar med nominasjonskomiteens forslag vedtok generalforsamlingen følgende sammensetning av nominasjonskomiteen:

- Leiv Askvig (leder)
- Dag Strømme
- Birgitte Gangmark Villmo
- Svein Kvåle

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

7 HONORAR TIL STYRETS MEDLEMMER

I samsvar med nominasjonskomiteens forslag vedtok generalforsamlingen følgende honorar til styrets medlemmer for perioden fra ordinær generalforsamling i 2023 til ordinær generalforsamling i 2024:

"Generalforsamlingen godkjenner følgende honorar til styrets medlemmer:

- *Styrets leder: NOK 450.000 per år*
- *Nestleder: NOK 400.000 per år*
- *Øvrige styremedlemmer: NOK 250.000 per år*

- Ann-Tove Kongsnes

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

6 ELECTION OF NOMINATION COMMITTEE

All members of the Nomination Committee are up for election.

In accordance with the Nomination Committee's proposal, the following Nomination Committee composition was made:

- Leiv Askvig (Chair)
- Dag Strømme
- Birgitte Gangmark Villmo
- Svein Kvåle

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

7 REMUNERATION TO THE MEMBERS OF THE BOARD OF DIRECTORS

In accordance with the Nomination Committee's proposal the following resolution regarding remuneration to the members of the Board of Directors for the period from the Annual General Meeting in 2023 to 2024 was made:

"The General Meeting approves the following remuneration to the members of the Board of Directors:

- *The Chair of the Board of Directors: NOK 450,000 per year*
- *Deputy chair: NOK 400,000 per year*

- *Other members of the Board of Directors: NOK 250,000 per year*

Honoraret utbetales som kontantbeløp hvert kvartal."

The remuneration is paid quarterly in cash."

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

8 HONORAR TIL MEDLEMMENE AV NOMINASJONSKOMITEEN

I samsvar med nominasjonskomiteens forslag vedtok generalforsamlingen følgende honorar til nominasjonskomiteens medlemmer for perioden fra ordinær generalforsamling i 2023 til ordinær generalforsamling i 2024:

"Generalforsamlingen godkjenner følgende honorar til nominasjonskomiteens medlemmer:

- *Komiteens leder: NOK 25.000.*
- *Øvrige medlemmer: NOK 15.000."*

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

8 REMUNERATION TO THE MEMBERS OF THE NOMINATION COMMITTEE

In accordance with the Nomination Committee's proposal the following resolution regarding remuneration to the members of the Nomination Committee for the period from the Annual General Meeting in 2023 to 2024 was made:

"The General Meeting approves the following remuneration to the members of the Nomination Committee:

- *The Chair of the committee: NOK 25,000*
- *Other members: NOK 15,000."*

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

9 HONORAR TIL MEDLEMMENE AV KOMPENSASJONSUTVALGET

I samsvar med nominasjonskomiteens forslag vedtok generalforsamlingen følgende honorar til kompensasjonsutvalget for perioden fra ordinær generalforsamling i 2023 til ordinær generalforsamling i 2024:

"Generalforsamlingen godkjenner følgende honorar til kompensasjonsutvalget medlemmer:

- *Komiteens leder: NOK 40.000*
- *Øvrige medlemmer: NOK 25.000*

9 REMUNERATION TO THE MEMBERS OF THE REMUNERATION COMMITTEE

In accordance with the Nomination Committee's proposal the following resolution regarding remuneration to the members of the Remuneration Committee for the period from the Annual General Meeting in 2023 to 2024 was made:

"The General Meeting approves the following remuneration to the members of the Remuneration Committee:

- *The Chair of the committee: NOK 40,000*
- *Other members: NOK 25,000*

Honoraret utbetales som kontantbeløp hvert kvartal." The remuneration is paid quarterly in cash."

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

10 HONORAR TIL MEDLEMMENE AV REVISJONSUTVALGET

I samsvar med nominasjonskomiteens forslag vedtok generalforsamlingen følgende honorar til revisjonsutvalget for perioden fra ordinær generalforsamling i 2023 til ordinær generalforsamling i 2024:

"Generalforsamlingen godkjenner følgende honorar til revisjonsutvalgets medlemmer:

- *Komiteens leder: NOK 40.000*
- *Øvrige medlemmer: NOK 25.000*

Honoraret utbetales som kontantbeløp hvert kvartal."

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

10 REMUNERATION TO THE MEMBERS OF THE AUDIT COMMITTEE

In accordance with the Nomination Committee's proposal the following resolution regarding remuneration to the members of the Audit Committee for the period from the Annual General Meeting in 2023 to 2024 was made:

"The General Meeting approves the following remuneration to the members of the Audit Committee:

- *The Chair of the committee: NOK 40,000*
- *Other members: NOK 25,000*

The remuneration is paid quarterly in cash."

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

11 VEDTEKSENDRINGER

I samsvar med styrets forslag ble følgende vedtatt:

Generalforsamlingen besluttet å endre vedtektenes § 6 til å lyde som følger:

"Selskapets styre består av 3 til 7 styremedlemmer etter generalforsamlingens nærmere beslutning. Selskapets styre herunder styreleder og nestleder velges årlig på ordinær generalforsamling.

Selskapets firma tegnes av styrets leder og ett styremedlem i fellesskap.

Styret kan meddele prokura.

Selskapet skal ha en daglig leder."

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

12 FULLMAKTER TIL STYRET TIL Å FORHØYE AKSJEKAPITALEN VED UTSTEDELSE AV NYE AKSJER

12.1 Styrefullmakt til kapitalforhøyelser i forbindelse med oppkjøp, etc.

I samsvar med styrets forslag ble følgende vedtatt:

"Selskapets styre tildeles fullmakt til å gjennomføre kapitalforhøyelse, på følgende vilkår:

- a) *Aksjekapitalen skal, i en eller flere omganger, kunne forhøyes med inntil NOK 23.997,80 tilsvarende 20 % av aksjekapitalen.*
- b) *Aksjonærenes fortrinnsrett etter aksjeloven § 10-4 kan fravikes av styret.*

11 AMENDMENTS OF THE ARTICLES OF ASSOCIATION

In accordance with the Board of Directors proposal, the following resolution was made:

The general meeting resolved to amend section 6 of the articles of association to read as follows:

"The board of directors consist of 3 to 7 members as decided by the general meeting. The board of directors, including the chairperson and deputy chairperson, is elected at the annual general meeting

The chairperson of the board and one director shall jointly have the right to sign on behalf of the company.

The board of directors can issue a registered power of attorney.

The Company shall have a managing director".

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

12 BOARD AUTHORISATIONS TO INCREASE THE SHARE CAPITAL BY ISSUANCE OF NEW SHARES

12.1 Board authorisation for share capital increases in connection with acquisitions, etc.

In accordance with the Board of Director's proposal, the following resolution was made:

"The Board is authorised to increase the Company's share capital, on the following conditions:

- a) *The share capital may, in one or more rounds, be increased by a total amount of up to NOK 23,997.80 corresponding to 20 % of the share capital.*
- b) *The preferential rights pursuant to Section 10-4 of the Private Limited*

Liability Companies Act may be set aside by the Board of Directors.

- | | |
|---|--|
| <p>c) Fullmakten gjelder fra registrering i Foretaksregisteret og frem til og med dato for ordinær generalforsamling i 2024, dog ikke senere enn 30. juni 2024.</p> | <p>c) The authorisation shall be effective from the date it is registered in the Norwegian Register of Business Enterprises and shall be valid until and including the date of the Annual General Meeting in 2024, however no later than 30 June 2024.</p> |
| <p>d) Fullmakten erstatter eksisterende fullmakt til kapitalforhøyelse gitt i ordinær generalforsamling 2021 når den blir registrert i Foretaksregisteret.</p> | <p>d) The authorisation replaces the current authorisation granted by the annual general meeting in 2021 when registered in the Norwegian Register of Business Enterprises.</p> |
| <p>e) Fullmakten skal omfatte kapitalforhøyelse mot innskudd i andre eiendeler enn penger, eller rett til å pådra Selskapet særlige plikter.</p> | <p>e) The authorisation covers share capital increases against or the right to assume special obligations on behalf of the Company.</p> |
| <p>f) Fullmakten omfatter kapitalforhøyelse i forbindelse med fusjon."</p> | <p>f) The authorisation covers share capital increases in connection with mergers."</p> |

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

12.2 Styrefullmakt til kapitalforhøyelser i forbindelse med Selskapets aksjeopsjonsprogram for nøkkelansatte og i forbindelse med styrekompensasjon

12.2 Board authorisation for share capital increases in connection with the Company's share options for Executive Management and in connection with Board compensation.

I samsvar med styrets forslag ble følgende vedtatt:

In accordance with the Board of Director's proposal, the following resolution was made:

"Selskapets styre tildeles fullmakt til å gjennomføre kapitalforhøyelse, på følgende vilkår:

"The Board is authorised to increase the Company's share capital, on the following conditions:

- | | |
|---|--|
| <p>a) Aksjekapitalen skal, i en eller flere omganger, kunne forhøyes med inntil NOK 5.999,45 tilsvarende 5 % av aksjekapitalen.</p> | <p>a) The share capital may, in one or more rounds, be increased by a total amount of up to NOK 5,999.45 corresponding to 5% of the share capital.</p> |
| <p>b) Aksjonærenes fortrinnsrett etter aksjeloven § 10-4 kan fravikes av styret.</p> | <p>b) The preferential rights pursuant to Section 10-4 of the Private Limited Liability Companies Act may be set aside by the Board of Directors.</p> |

- | | |
|---|--|
| c) <i>Fullmakten gjelder fra registrering i Foretaksregisteret og frem til og med dato for ordinær generalforsamling i 2024, dog ikke senere enn 30. juni 2024.</i> | c) <i>The authorisation shall be effective from the date it is registered in the Norwegian Register of Business Enterprises and shall be valid until and including the date of the Annual General Meeting in 2024, however no later than 30 June 2024.</i> |
| d) <i>Fullmakten skal ikke omfatte kapitalforhøyelse mot innskudd i andre eiendeler enn penger, eller rett til å pådra Selskapet særlige plikter.</i> | d) <i>The authorisation does not cover share capital increases against or the right to assume special obligations on behalf of the Company.</i> |
| e) <i>Fullmakten omfatter ikke kapitalforhøyelse i forbindelse med fusjon."</i> | e) <i>The authorisation does not cover share capital increases in connection with mergers."</i> |

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

Oslo, June 9, 2023

DocuSigned by:

Anders Wold

57429969E76B43E

Anders Wold

(møteleder / Chair of the meeting)

DocuSigned by:

John M. Edminson

GD98F382D1A74FF...

John M. Edminson

(medundertegner / co-signer)

Vedlegg/ Appendices:

1. Fortegnelse over møtende aksjeeiere, inkludert antall aksjer og stemmer representert/
Record of attending shareholders, including the number of shares and votes represented
2. Stemmeresultater/ Voting results

**FORTEGNELSE OVER MØTENDE AKSJEIERE, INKLUDERT ANTALL AKSJER OG STEMMER REPRESENTERT
/ RECORD OF ATTENDING SHAREHOLDERS, INCLUDING THE NUMBER OF SHARES AND VOTES
REPRESENTED**

Represented list EXACT THERAPEUTICS AS				
Ref no	First Name	Company/Last name	Holdings	Repr. by
18		KVÅLE AS	3 024 270	
26		PAACS INVEST AS	2 691 509	
42		BREKKE HOLDING AS	2 375 628	
59	ANDREW JOHN	HEALEY	2 205 385	
75	PER CHRISTIAN	SONTUM	1 922 105	
83		OPTIMUSPISTOR AS	1 574 750	
91		VERDIPAPIRFONDET NORDEA AVKASTNING	1 244 999	
141		Danske Invest Norge Vekst	590 750	
240		TRI-LI HOLDING AS	187 750	
257		GRATIUS AS	187 750	
265		PEGUS AS	186 250	
844	ANDERS	WOLD	4 914	
1 065	JOHN MORTEN	EDMINSON	2 500	
1 073	PER EDVARD	WALDAY	2 500	
1 156	KNUT	MÆHLUM	2 000	
2 410	ARVID	HEFTE	65	

VEDLEGG 2 / APPENDIX 2
STEMMERESULTATER / VOTING RESULTS

Total Represented


ISIN: NO0010852213 EXACT THERAPEUTICS AS
General meeting date: 09/06/2023 10.30
Today: 09.06.2023

Number of persons with voting rights represented/attended : 2

	Number of shares	% sc
Total shares	29,997,219	
- own shares of the company	0	
Total shares with voting rights	29,997,219	
Represented by own shares	4,914	0.02 %
Sum own shares	4,914	0.02 %
Represented by proxy	14,362,462	47.88 %
Represented by voting instruction	1,835,749	6.12 %
Sum proxy shares	16,198,211	54.00 %
Total represented with voting rights	16,203,125	54.02 %
Total represented by share capital	16,203,125	54.02 %


Registrar for the company:

DNB Bank ASA



Signature company:

EXACT THERAPEUTICS AS
DocuSigned by:


57429969F76B43E...

DNB Bank ASA
Registrars Department

Protocol for general meeting EXACT THERAPEUTICS AS

ISIN: [NO0010852213 EXACT THERAPEUTICS AS](#)
 General meeting date: 09/06/2023 10.30
 Today: 09.06.2023

Shares class	FOR	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Agenda item 1 Opening of the general meeting, approval of the summons and agenda						
Ordinær	16,203,125	0	16,203,125	0	0	16,203,125
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.02 %	0.00 %	54.02 %	0.00 %	0.00 %	
Total	16,203,125	0	16,203,125	0	0	16,203,125
Agenda item 2 Election of chair and person to co-sign the minutes						
Ordinær	16,203,125	0	16,203,125	0	0	16,203,125
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.02 %	0.00 %	54.02 %	0.00 %	0.00 %	
Total	16,203,125	0	16,203,125	0	0	16,203,125
Agenda item 3 Approval of the financial statements and the board of directors' report						
Ordinær	16,203,125	0	16,203,125	0	0	16,203,125
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.02 %	0.00 %	54.02 %	0.00 %	0.00 %	
Total	16,203,125	0	16,203,125	0	0	16,203,125
Agenda item 4 Approval of the auditor's remuneration						
Ordinær	16,203,125	0	16,203,125	0	0	16,203,125
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.02 %	0.00 %	54.02 %	0.00 %	0.00 %	
Total	16,203,125	0	16,203,125	0	0	16,203,125
Agenda item 5 Election of board members						
Ordinær	16,203,125	0	16,203,125	0	0	16,203,125
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.02 %	0.00 %	54.02 %	0.00 %	0.00 %	
Total	16,203,125	0	16,203,125	0	0	16,203,125
Agenda item 6 Election of nomination committee						
Ordinær	14,958,126	1,244,999	16,203,125	0	0	16,203,125
votes cast in %	92.32 %	7.68 %		0.00 %		
representation of sc in %	92.32 %	7.68 %	100.00 %	0.00 %	0.00 %	
total sc in %	49.87 %	4.15 %	54.02 %	0.00 %	0.00 %	
Total	14,958,126	1,244,999	16,203,125	0	0	16,203,125
Agenda item 7 Remuneration to the members of the board of directors						
Ordinær	16,203,125	0	16,203,125	0	0	16,203,125
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.02 %	0.00 %	54.02 %	0.00 %	0.00 %	
Total	16,203,125	0	16,203,125	0	0	16,203,125
Agenda item 8 Remuneration to the members of the nomination committee						
Ordinær	16,203,125	0	16,203,125	0	0	16,203,125
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.02 %	0.00 %	54.02 %	0.00 %	0.00 %	
Total	16,203,125	0	16,203,125	0	0	16,203,125
Agenda item 9 Remuneration to the members of remuneration committee						
Ordinær	16,203,125	0	16,203,125	0	0	16,203,125
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.02 %	0.00 %	54.02 %	0.00 %	0.00 %	
Total	16,203,125	0	16,203,125	0	0	16,203,125
Agenda item 10 Remuneration to the members of the audit committee						
Ordinær	16,203,125	0	16,203,125	0	0	16,203,125

Shares class	FOR	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.02 %	0.00 %	54.02 %	0.00 %	0.00 %	
Total	16,203,125	0	16,203,125	0	0	16,203,125
Agenda item 11 Amendments of the articles of association						
Ordinær	16,203,125	0	16,203,125	0	0	16,203,125
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.02 %	0.00 %	54.02 %	0.00 %	0.00 %	
Total	16,203,125	0	16,203,125	0	0	16,203,125
Agenda item 12.1 Board authorisation for share capital increase in order to finance growth						
Ordinær	14,367,376	1,835,749	16,203,125	0	0	16,203,125
votes cast in %	88.67 %	11.33 %		0.00 %		
representation of sc in %	88.67 %	11.33 %	100.00 %	0.00 %	0.00 %	
total sc in %	47.90 %	6.12 %	54.02 %	0.00 %	0.00 %	
Total	14,367,376	1,835,749	16,203,125	0	0	16,203,125
Agenda item 12.2 Board authorisation for share capital increases in connection with the Company's share options for Executive Management and in connection						
Ordinær	14,958,126	1,244,999	16,203,125	0	0	16,203,125
votes cast in %	92.32 %	7.68 %		0.00 %		
representation of sc in %	92.32 %	7.68 %	100.00 %	0.00 %	0.00 %	
total sc in %	49.87 %	4.15 %	54.02 %	0.00 %	0.00 %	
Total	14,958,126	1,244,999	16,203,125	0	0	16,203,125

Registrar for the company:

DNB Bank ASA

Rasmus Bjørnstad

Signature company:

EXACT THERAPEUTICS AS

DocuSigned by:

Anders Wold

57429969F76B43E...

Share information

Name	Total number of shares	Nominal value	Share capital	Voting rights
Ordinær	29,997,219	0.00	119,988.88	Yes
Sum:				

§ 5-17 Generally majority requirement

requires majority of the given votes

§ 5-18 Amendment to resolution

Requires two-thirds majority of the given votes

like the issued share capital represented/attended on the general meeting

DNB Bank ASA
Registrars Department